Vimarsana
Biggest News Aggregation in the World

Page 16 - Advanced Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Solid Tumors Today - Breaking & Trending Today

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation | Small Molecules - Vimarsana News

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation | Small Molecules

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation

First Patient Dosed in Australia in ATG-101 First-in-Human Trial - Vimarsana News

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

Study to evaluate ATG-101, a proprietary PD-L1/4-1BB bispecific antibody Study will enroll patients with Metastatic/Advanced Solid Tumors and Mature B-Cell Non-Hodgkin Lymphomas SHANGHAI and HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced...

First Patient Dosed in Australia in ATG-101 First-in-Human Trial - Vimarsana News

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

Study to evaluate ATG-101, a proprietary PD-L1/4-1BB bispecific antibody Study will enroll patients with Metastatic/Advanced Solid Tumors and Mature B-Cell...

First Patient Dosed in Australia in ATG-101 First-in-Human Trial - Vimarsana News

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

Study to evaluate ATG-101, a proprietary PD-L1/4-1BB bispecific antibody Study will enroll patients with Metastatic/Advanced Solid Tumors and Mature B-Cell...

Imugene Limited secures FDA approval for two clinical trials of promising oncology drug candidates - Vimarsana News

Imugene Limited secures FDA approval for two clinical trials of promising oncology drug candidates

“To achieve two INDs for our programs (OV and B Cell) concurrently is an outstanding result for the team," says MD.